Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Berberine hydrochloride in carotid atherosclerosis, middle cerebral artery stenosis, and hyperhomocysteinemia
ChiCTR2000029838Phase 4Recruiting
- Sponsor
- Baoding No. 1 Central Hospital
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of berberine in carotid atheroma (CAS), middle cerebral artery atherosclerosis, hyperhomocysteinemia and 1 more (7 arms), sponsored by Baoding No. 1 Central Hospital. Primary endpoints: Homocysteine at 24 weeks, Middle cerebral artery stenosis at 24 weeks and 2 more. Started Jan 2018; status: recruiting.
02
Drugs
berberine
03
Conditions
carotid atheroma (CAS)middle cerebral artery atherosclerosishyperhomocysteinemiaischemic stroke
Beyond the preview
Go deeper on ChiCTR2000029838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000029838.